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Abstract
Background: This split-mouth, double-blind randomized controlled trial evaluated radiographic changes in infrabony
defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD) after a
24–month follow-up. The radiographic distance from the CEJ to the bottom of the defect (BD) was considered the
primary outcome. CEJ-BC and defect angle were secondary outcomes.
Methods: Ten patients presenting 2 or more defects were selected. An individualized film holder was used to take
standardized radiographs of the 43 defects, at baseline and after 24 months. Images were digitized and used to measure
the distances from the cemento-enamel junction (CEJ) to the alveolar crest (AC), CEJ to the bottom of the defect (BD)
and infrabony defect angle. Statistical analysis was performed in SPSS for Windows (version 5.2). Paired samples t test
was used to compare test and control groups and to evaluate changes within each group. The level of significance was
set at α = 0.05%.
Results: After 24 months, a significant crestal bone loss was observed for EMD (1.01 mm; p = 0.049) but not for OFD
(0.14 mm; p = 0.622). However, no differences were detected between groups (p = 0.37). Reduction of the bone defect
depth was significant for OFD (0.70 mm; p = 0.005) but not for EMD (0.04 mm; p = 0.86), while no differences were
detected between them (p = 0.87). Both EMD (0.69°; p = 0.82) and OFD (5.71°; p = 0.24) showed an improvement in
defect angle measurements but no significant differences were observed after 24 months or between the groups
(p = 0.35).
Conclusion: Linear radiographic analysis was not able to demonstrate superiority of EMD treated infrabony defects
when compared to ODF after 24 months.
Trial registration: ClinicalTrials.gov: NCT02195765. Registered 17 July 2014.
Keywords: Periodontal regeneration, Enamel matrix derivative, Radiographic analysis, Randomized controlled clinical
trial, Infrabony defect
Background
The main goal of periodontal therapy is to halt the de-
structive process while the ideal objective of periodontal
surgery is to regenerate the lost tissues. Regeneration in
Periodontics seeks reproduction or reconstitution of a
lost or injured part [1], namely formation of new cemen-
tum, new alveolar bone, and a functional periodontal
ligament.
Different approaches have been proposed to obtain re-
generation of periodontal tissues, such as bone grafts,
alloplastic materials, guided tissue regeneration, growth
factors and enamel matrix derivative (EMD). EMD is
known to play a role in the tooth formation, particularly
in the formation of acellular cementum [2]. Lately, the
use of EMD has been proposed as an alternative in peri-
odontal regeneration. Various studies were performed to
evaluate the potential of obtaining periodontal regener-
ation with this material. In vitro studies and animal stud-
ies tend to show a benefit on the application of EMD
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[2-4]. However, prospective controlled clinical trials es-
tablishing scientific evidence for the clinical usefulness
of EMD are scarce and contradictory [5-14].
Assessment of regenerative procedures is necessary for
the evaluation of periodontal therapy. The methods used
for evaluation include histology, re-entry surgery, peri-
odontal probing and radiographic analysis [15]. Among
those methods, few prospective randomized controlled
clinical trials used computerized linear radiographic mea-
surements to evaluate the EMD's application in infrabony
defects. Eight clinical trials used clinical and radiographic
parameters to evaluate the effect of EMD in infrabony de-
fects [5-9,11,13,14]. Some studies [5-8,14] observed better
results in test groups (EMD) than in control groups (pla-
cebo). The EMD groups showed more reduction in prob-
ing pocket depth with concomitant gain in periodontal
attachment level and increased radiographic bone gain.
However, other studies [9,11,13] did not demonstrate su-
periority of EMD in relation to control group. In a recent
systematic review [16] about the use of EMD for peri-
odontal tissue regeneration in infrabony defects, only
three studies that evaluated radiographic changes were
considered at low risk of bias [5,9,11]. There was no sig-
nificant difference between the EMD and the control
group regarding radiographic bone gain [16].
The high degree of heterogeneity observed among trials
suggests that results have to be interpreted with caution
[16]. In light of the available scientific evidence, it is not
possible to know the actual clinical advantages of EMD yet
[16]. Hence, prospective randomized controlled clinical tri-
als are needed to confirm the clinical and radiographic effi-
cacy of this method for periodontal regeneration.
Thus, the aim of the present study was to compare
periodontal radiographic parameters after the treatment
of infrabony defects with open flap debridement (OFD)
combined or not with enamel matrix derivative (EMD)
after 24 months.
Methods
Subjects
This split-mouth randomized controlled trial was per-
formed at the Department of Periodontics of the University
of São Paulo (São Paulo, Brazil). The project was approved
by the Institution's Research Ethics Committee (University
of Sao Paulo - School of Dentistry), protocol number 220/
03, in accordance with the Helsinki Declaration of 1975, as
revised in 2000. Patients were recruited among those who
sought periodontal treatment at the Post-graduate Clinic
of Periodontics. The following inclusion criteria were con-
sidered: (1) diagnosis of chronic periodontitis [17]; (2) pres-
ence of at least one pair of interproximal infrabony defects
(2–3 walls) adjacent to vital anterior or premolar teeth; (3)
absence of degree mobility 3 [18]; (4) probing pocket depth
(PPD) ≥ 5 mm; (5) full-mouth plaque score ≤20% [19]; and
(6) keratinized tissue width of at least 2 mm. The exclusion
criteria were: (1) presence of any systemic disease that
could interfere with periodontal treatment; (2) infrabony
defects with trans-surgical depth ≤4 mm; (3) antibiotic
treatment within the last 6 months. Patients who volun-
teered to participate in the study gave informed consent
and were recruited from June to October 2002.
Clinical procedures
Following initial examination, all patients were given
oral hygiene instruction and full-mouth supra- and sub-
gingival scaling and root planning under local anesthesia.
Patients were re-evaluated after 4–6 weeks of the initial
therapy to determine their response to therapy and to
confirm the need for periodontal surgery.
All surgical procedures, until the defects were com-
pletely debrided were performed by the same operator
(DC). Treatment modality was assigned to each defect
by a flip of a coin (MC) to receive either EMD following
OFD or OFD alone. Following local anesthesia, all sites
were treated with reflection of a full thickness mucoper-
iosteal flap after intra-sulcular incisions. The exposed
roots and osseous defects were debrided with hand in-
struments, and the surgical wound was rinsed with sa-
line. The first surgeon (DC) left the room in order to
keep the study blinded. Another surgeon (MC) treated
the selected sites with Prefgel and Emdogain (MC).
Both defects were treated at the same surgical time.
Adjacent sites were treated by the same therapy while
sites localized in the opposite side of the arch were
treated differently.
After that, the flaps of the OFD sites were repositioned
and sutured using 5–0 nylon sutures (Tech-Lon, Tech-
Synt/Lukens). The EMD sites were dried with non-woven
gauze, roots were conditioned with 24% ethylenediamino-
tetracetic acid (EDTA) gel (pH 6.7; Prefgel, Straumann)
for 2 minutes. The defect was thoroughly rinsed with sa-
line, and EMD (Emdogain, Straumann) gel was applied to
the root surfaces according to the manufacturer’s instruc-
tions. The flaps were then replaced and sutured with 5–0
nylon sutures. The sutures were removed after 7 days.
All patients were prescribed 0.12% chlorhexidine diglu-
conate and instructed to rinse gently twice a day for
4 weeks. Analgesics were prescribed to be taken as needed.
All patients returned for professional tooth cleaning once a
week, for 8 weeks. Only supragingival instrumentation was
performed during supportive periodontal treatment. Subse-
quently, the patients were maintained in a supportive peri-
odontal program (ie, professional tooth cleaning and
reinforcement of self-administered oral hygiene measures)
at 2-month intervals up to 6-months and then every
3 months until the final examination at 24 months. Clinical
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results of the present RCT were presented elsewhere
[10,12].
Radiographic evaluation
Standardized periapical radiographs were taken at baseline
evaluation, immediately before surgery and after 24 months.
Individually customized bite blocks employing a reference
occlusal stent and film holders were used to obtain repro-
ducible exposed films at each radiographic control. All
radiographic images were evaluated by a single examiner
blind to treatment and follow-up period (MSRZ). Analyses
of the radiographic outcomes were performed using com-
puterized linear measurements with image analysis software
(Axiovision v. 3.0; Carl Zeiss). The radiographs were previ-
ously scanned in digital format by a scanner (SprintScan
35, Polaroid) at a resolution of 500dpi/8bits. Calibration of
the software was achieved with a 1×1 mm radiographic
grid. The radiographic analysis was based in anatomical
landmarks (CEJ, BD and AC) that were identified on the
scanned radiographs.
All linear measurements were recorded by a blinded,
calibrated examiner (MSRZ) (intra-class correlation coeffi-
cient = 0.98). Each parameter was evaluated using 10 pairs
of radiographs (baseline and 24 months) in two stages,
with an interval of 15 days between two assessments.
The following outcomes were measured at baseline and
after 24 months:
1. Distance from the CEJ to the bottom of the defect
(BD). The most coronal area where the periodontal
ligament maintained an even width was identified to
measure the most apical extension of the infrabony
defect [20] (Figure 1);
2. Distance from the CEJ to the bone crest (BC)
(Figure 2);
3. Infrabony defect angle was defined by two lines that
represented the root surface of the involved tooth
(CEJ-BD) and the bone defect surface (BD-BC) [21]
(Figure 3).
Sample size calculation
The distance from the CEJ to the bottom of the defect
(BD) was considered the primary outcome. CEJ-BC and
defect angle were secondary outcomes. Based on a 0.8
power to detect a significant difference of 2.0 mm in
CEJ-BD (α = 0.05; SD = 2.0 mm), 12 volunteers would
be required for the trial. Sample size calculation was
conducted considering the split-mouth design, in which
experimental groups are paired.
Statistical analysis
Initially, as most patients presented more than one pair
of infrabony defects, individual site data were grouped
and converted as means of each subject, according to
the treatment group. Subsequently, means, medians, and
standard deviations for the variables CEJ-BC, CEJ-BD,
and defect angle were calculated for both groups (ie, EMD
and OFD) using patient as the unit of analysis. Taking into
account the nature of the split-mouth design, where both
experimental groups are related, paired samples t test was
used to compare test and control groups and to analyze
changes within each group from baseline to the 24-month
examination. Adherence to normal distribution was veri-
fied using Kolmogorov-Smirnov test. Data had been regis-
tered in an elaborated database in Excel (version 7.0). The
statistical analysis was performed in SPSS program for
Windows (version 5.2). The level of significance was set at
α = 0.05%.
Results
Figure 4 illustrates the study flowchart according to CON-
SORT guidelines. At 24 months follow up, 10 patients
(two men and eight women; three smokers and seven
non-smokers) 28 to 50 years old (38.8 ± 5.7), with 43
infrabony defects (ie, 18 defects in the control group and
Figure 1 Distance from CEJ to BD.
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25 in the test group) were analyzed for the primary and
secondary outcomes.
Postoperative healing was uneventful in all cases, and no
complications or adverse effects were observed through-
out the study period.
Table 1 reports the mean and standard deviations of the
distance CEJ-AC and CEJ-BD for experimental groups at
baseline and after 24 months. There were no differences
in CEJ-AC values between groups at baseline. After
24 months, a significant crestal bone loss (CEJ-AC) was
observed for EMD (1.01 mm; p = 0.049) but not for OFD
(0.14 mm; p = 0.622). However, no differences were de-
tected between groups (p = 0.37). At baseline, mean
value of CEJ-BD was 10.11 for test group and 8.67 for
control, with no statistical difference between groups.
After 24 months, reduction of the bone defect depth
(CEJ-BD) was significant for OFD (0.70 mm; p = 0.005)
but not for EMD (−0.04 mm; p = 0.86), while no differ-
ences were detected between them (p = 0.87).
Table 2 shows the mean and median values and stand-
ard deviations of defect angle for experimental groups at
baseline and after 24 months. At baseline, the mean
value of defect angle was the same for test and control
group (29.64°). Both EMD (0.69°; p = 0.82) and OFD
(5.71°; p = 0.24) showed an improvement in defect angle
measurements but no significant differences were ob-
served after 24 months or between them (p = 0.35).
Discussion
After 24 months, inter-group comparisons (EMD versus
OFD) showed that the use of EMD did not present add-
itional benefits in radiographic measurements. Reduction of
the bone defect depth was significant in OFD group
(0.7 mm; p = 0.005) but not for the test group (−0.04 mm;
p = 0.86). However, no differences were detected between
groups for both parameters. In accordance with the present
results, other investigators which evaluated radiographic
measurements did not find differences between groups
after 12 months (EMD = 1.55 mm; Placebo = 1.39 mm,
p = 0.9) [9], (EMD = 2.5 mm; Placebo = 2.5 mm, p = 0.81)
[11]. Nevertheless, previous clinical trials showed greater
mean radiographic bone gain for EMD group: 2.6 mm [5],
2.4 mm [6] and 3.44 mm [8]. Regarding the crestal bone,
there was significant crestal bone loss in the test group
(1.01 mm; p = 0.049) but not for the control group
(0.14 mm; p = 0.622) with no differences between groups. A
limitation of the present trial was the reduced sample size
and consequent low power to detect differences between
Figure 2 Distance from CEJ to AC. Figure 3 Angle formed between lines CEJ-BD and CEJ-AC.
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groups. In agreement with the results of this study, other
trials [9,11,13] did not find differences between groups. Re-
sults of this study regarding angle of the defects have shown
that at baseline, mean values of defect angle were the same
(29.64°) for both groups. Both EMD (0.69°; p = 0.82) and
OFD (5.71°; p = 0.24) showed an improvement in defect
angle measurements but no significant differences were ob-
served after 24 months or between them (p = 0.35). In this
study, EMD was not able to produce additional radio-
graphic benefits compared with the OFD alone. In contrast,
Francetti et al. [8] observed that in EMD group, infrabony
defect angle (IBA) at either 12 (50.2°) or 24 months
(51.7°) was significantly increased when compared with
baseline (31.7°). In the control group, IBA did not show
significant changes at 12 (40.2°) and 24 months (41.3°)
with respect to baseline (32.5°). A significant difference
between groups was found for the 12-month but not
for the 24-month follow-up. According to Steffensen
and Weber [21] the presence of a defect angle lower
than 45° would be more favorable to radiographic bone
healing. Although defect angle was lower than 45° in
the present study. we could not observe a favorable re-
sult. These results might be justified because of the
inherent variability of results achieved with EMD tech-
nique [16] or due to the fact that three of our subjects
were smokers [22].
Figure 4 Flowchart for study patients.
Table 1 Mean, standard deviation and comparison of
experimental groups for CEJ-AC and CEJ-BD
(N = 10 patients)
Time period Mean/SD EMD (mm) OFD (mm) Paired t test
Baseline Mean 5.13 5.10 0.35
CEJ-AC SD 2.59 2.31
24 months Mean 6.14 5.24 0.37
CEJ-AC SD 2.47 2.73
Paired t test 0.049* 0.622
Baseline Mean 10.11 8.67 0.93
CEJ-BD SD 2.63 2.43
24 months Mean 10.15 7.97 0.87
CEJ-BD SD 2.78 2.29
Paired t test 0.86 0.005*
SD = standard deviation, *statistical significance 0.05%.
Table 2 Mean, median, standard deviation and
comparison of experimental groups for defect angle
(N = 10 patients)
Time period Mean/SD EMD (mm) OFD (mm) Paired t test
Baseline Mean 29.64 29.64 0.99
Median 25.99 32.71
SD 9.65 12.39
24 months Mean 30.33 35.35 0.35
Median 27.05 34.30
SD 11.21 16.53
Paired t test 0.82 0.24
SD = standard deviation.
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Clinical parameters (relative attachment level-RAL, peri-
odontal probing depth-PPD, plaque index-PI and gingival
index-GI) were evaluated at 6, 12, 18 and 24 months of
follow up [10,12]. Both procedures (EMD and OFD) were
effective in reducing PPD, with concomitant gain in RAL
(p < 0.05). Compared with baseline data, the 24-month
examination showed a mean reduction in PPD of 4.21 ±
0.97 mm for the test group and 3.28 ± 1.23 mm for the
control group. The reduction was statistically significant
for EMD group. Mean gain in RAL was 5.69 ± 1.96 mm
for test group and 5.24 ± 1.55 mm for control group. How-
ever, no differences were detected between groups. Both
groups presented a significant reduction of PI and GI
throughout the experiment. Although favorable clinical re-
sults were achieved for both groups, none of the two
above clinical parameters represent or correlate to bone
levels. These aspects stress the importance of radiographic
evaluation of regenerative procedures and justify the re-
sults of the present study due to the fact that the clinical
improvement achieved with EMD and OFD may not be
expressed to the same extent on bone levels. Studies
[23,24] evaluating periodontal regeneration also found no
correlation between clinical parameters and radiographic
bone linear measurements or subtraction analysis.
According to Zanatta et al. [25], it is evident that clin-
ical and radiographic methods are not safe in the deter-
mination of the healing pattern that occurs after
regenerative therapy. Thus, in vitro studies support the
concept that EMD may enhance periodontal regener-
ation with formation of acellular cementum and stimula-
tion of periodontal ligament cells [2,26]. Conversely,
EMD effects on osteoblastic cells were variable accord-
ing to the cell species and/or culture conditions [27].
Hama et al. [27] reported that EMD may function ini-
tially to inhibit osteoblastic differentiation to allow a pre-
dominant formation of other periodontal tissues.
Plachokova et al. [28] concluded that Emdogain is not
osteoinductive and does not provide an additional
stimulus for bone formation. This in vivo study demon-
strated that use of EMD for the purpose of generating
new bone in clinical situations should be questioned.
Windisch et al. [29] observed less bone formation for
EMD compared to guided tissue regeneration group, but
with improvement of clinical parameters in both groups.
Even in the absence of bone, the presence of periodontal
ligament cells is sufficient for fibrous reattachment be-
tween root surface and the surrounding tissue [30].
These findings are also important from a clinical point
of view, since they indicate that the absence of a radio-
graphic defect fill does not necessarily imply in failure of
the therapy [29]. Based on a previously published study
[12] with favorable clinical outcomes in this sample, it is
possible to infer that clinical attachment gain occurred,
but without defect bone fill.
As a matter of fact, the present study showed lower
mean values of radiographic bone fill compared with the
literature. Nevertheless, it is important to report that out
of 43 bone defects, 60.46% presented bone gain (CEJ-BD),
46.15% (mean gain = 1.3 mm) from test group and 53.85%
(mean gain = 1.04 mm) from control. Bone loss occurred
in 37.2% sites, being 75% (mean loss = 1.06 mm) in test
sites and 25% (mean loss = 0.49 mm) in control sites.
The variability of results obtained in different trials
might be related to diverse aspects such as the place
where the study was conducted, inclusion of smokers,
type of infrabony defects treated, type of periodontal dis-
ease, persistence of specific periodontal pathogens, dif-
ferences in the technical ability and experience of the
clinician and capacity of clinical organization and data
collection [31], use of placebo, antibiotics, differences in
surgical techniques and root conditioning [16].
The small sample size and inclusion of smokers
might have contributed for the unfavorable results ob-
served in the present study. Tobacco smoking is known
to produce negative effects on periodontal regenerative
therapy [22,32,33]. Two clinical trials [11,13] reported
lack of a statistical difference between EMD and
placebo-treated sites. One [11] attributed part of this
outcome to tobacco use, since there were more heavy
smokers in the test group, although the other trial [13]
excluded smokers.
A systematic review and meta-analysis [25] suggested that
the magnitude of differences between the use of EMD and
OFD considerably decreases over time, when studies with
follow-up of 12 months and follow up ≥24 months are
compared. Considering the quality of the included studies,
those with low risk of bias showed lower differences be-
tween groups. In the systematic review by Esposito et al.
[16], out of 35 studies, only three trials were selected for
radiographic analysis [5,9,11]. This findings stress the im-
portance of producing more data on radiographic analysis
of EMD. Meta-analysis of nine trials demonstrated that
the application of EMD showed improvements in peri-
odontal attachment level (PAL = 1.1 mm) and PPD reduc-
tion (PPD = 0.9 mm). While the improvements in PAL
and PPD levels were positive findings, the real clinical util-
ity of EMD was debated. In particular, it was reported that
there is no evidence that more compromised teeth could
be saved or the amount of tissue regeneration is clinically
significant [16].
With respect to generalization of the findings, in this
study, treatments were administered by an experienced
clinician which is not always the case in a clinical set-
ting. Moreover, a very strict maintenance regimen was
adopted, which also is not generally a routine in clinical
situations. Even considering these restrictive conditions,
the results presented high variability and low clinical sig-
nificance [16].
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Conclusions
Although the application of EMD for periodontal regen-
eration may result in favorable clinical outcomes, we did
not observe an additional benefit on bone gain. Linear
radiographic analysis was not able to demonstrate super-
iority of EMD treated infrabony defects when compared
to ODF after 24 months. Evidences of the efficacy of
EMD on the treatment of infrabony defects are conflict-
ing. More randomized controlled clinical trials, with low
risk of bias and larger samples, are necessary to further
investigate if there are actual clinical and radiographic
advantages of using EMD for periodontal regenerative
therapy.
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